Clinical Trial Update: Safety of SPD417 Combined With Other Psychotropic Medications in the Treatment of Bipolar I Disorder [Phase 3]

View source ↗

Summary

Phase 3 safety update of SPD417 when combined with other psychotropic medications for Bipolar I disorder has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder

Drugs mentioned

• SPD417 (SPD417)

Snippet

Sponsor: Validus Pharmaceuticals | Conditions: Bipolar Disorder | Phase 3 | Status: COMPLETED